Next 10 |
home / stock / morf / morf articles
NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- Abraham, Fruchter & Twersky, LLP (https://aftlaw.com/), a nationally recognized law firm that f...
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of...
WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of or...
SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Morphic Holding, Inc. (NASDAQ:MORF) to d...
SAN DIEGO, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ:...
SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Morphic Holding, Inc. (NASDAQ:MORF) to d...
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Por...
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Mo...
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Mo...
News, Short Squeeze, Breakout and More Instantly...
Morphic Holding Inc. Company Name:
MORF Stock Symbol:
NYSE Market:
2024-05-02 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disea...
Kiniksa Pharmaceuticals Ltd. (KNSA) is expected to report $-0.14 for Q1 2024 Agree Realty Corporation (ADC) is expected to report $1.01 for Q1 2024 1st Colonial Bancorp Inc (FCOB) is expected to report for Q1 2024 Equity Residential of Beneficial Interest (EQR) is expected to report $...